Emalex Biosciences
Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders. The company's first development candidate Ecopipam, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. Emalex Biosciences was founded in 2018 by Jeff Aronin.
Domain
emalexbiosciences.com
Country
United StatesIndustry
BiopharmaEmployees
11-50
Last Funding
$270.0M
Founded
2017
Tech Stack (23 technologies)
Frequently Asked Questions
What technologies does Emalex Biosciences use?+
Emalex Biosciences uses 23 technologies including GeneratePress, Google Analytics, Google Tag Manager.
What industry is Emalex Biosciences in?+
Emalex Biosciences operates in the Biopharma industry.
Where is Emalex Biosciences based?+
Emalex Biosciences is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026